FivePrime waves bye to CEO; Allos moves into PhIII with lymphoma drug;

@FierceBiotech: Stanford investigators use "online dating" to match old drugs with new medical uses. Story | Follow @FierceBiotech

@JohnCFierce: Funny Icahn threat in conceding Forest BOD vote. Imclone, Biogen, Genzyme all took time. (I'll be baa-a-a-ack.) More | Follow @JohnCFierce

@RyanMFierce: Hmm. Ireland-based academic says that private biotech spin-offs do better than those from universities Piece | Follow @RyanMFierce

@MaureenFierce: The other dark side of Merck's 13,000 layoffs: Pharma's moving to greener pastures. Story | Follow @MaureenFierce

> FivePrime Therapeutics' CEO, Julia Gregory, has resigned from her post and company founder Lewis Williams is now listed as the firm's chief executive. In Vivo report

> The Irish Times reports a study that found that private-sector biotech spin-offs "outperform" their counterparts from universities. Article

> Allos Therpeutics ($ALTH) reports that it has begun a Phase III trial of Folotyn for patients with certain cases of peripheral T-cell lymphoma. Item

> Apricus Biosciences says ($APRI) says that the FDA has cleared its subsidiary's over-the-counter anti-fungal drug, Tolnaftate-D. Apricus release

> With plans to fund its clinical-stage compounds, Furiex Pharmaceuticals ($FURX) has garnered a loan deal from MidCap Financial and Silicon Valley Bank that enables the firm to get up to $15 million. Announcement

Pharma News

@FiercePharma: Ranbaxy could waive Lipitor rights, let a rival generic to market... for a fee. If it can't get straight with FDA first. Article | Follow @FiercePharma

> Paladin CEO in hospital after cycling accident. Article

> Japan asks Boehringer to warn docs on Pradaxa. Report

> Drugmakers take a hit on Greek bonds. News

> Vertex's Incivek could top $1B this year, analyst says. Item

And Finally... One in 5 people seeking bankruptcy protection blames medical bills. Report

Suggested Articles

Sethi spent the past four years at AstraZeneca, rising to the post of chief physician scientist at its clinical discovery unit.

Contract research organization PPD is expanding its Richmond, Virginia, lab by adding 200 new staffers and boosting its research capabilities.

Omega Therapeutics is working on treatments that adjust gene expression up or down without making permanent changes to the genome.